vs
Side-by-side financial comparison of Mind Medicine (MindMed) Inc. (DFTX) and GAXOS.AI INC. (GXAI). Click either name above to swap in a different company.
GAXOS.AI INC. is the larger business by last-quarter revenue ($1.2M vs $906.0K, roughly 1.4× Mind Medicine (MindMed) Inc.). GAXOS.AI INC. runs the higher net margin — -77.2% vs -2634.0%, a 2556.7% gap on every dollar of revenue. On growth, GAXOS.AI INC. posted the faster year-over-year revenue change (94996.3% vs -16.1%).
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
DFTX vs GXAI — Head-to-Head
Income Statement — Q4 FY2023 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $906.0K | $1.2M |
| Net Profit | $-23.9M | $-957.9K |
| Gross Margin | — | — |
| Operating Margin | -2450.8% | -99.0% |
| Net Margin | -2634.0% | -77.2% |
| Revenue YoY | -16.1% | 94996.3% |
| Net Profit YoY | -386.7% | -15.1% |
| EPS (diluted) | $-0.58 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.2M | ||
| Q3 25 | — | $498.3K | ||
| Q2 25 | — | $171.0K | ||
| Q2 24 | — | $0 | ||
| Q4 23 | $906.0K | — | ||
| Q3 23 | $1.2M | — | ||
| Q2 23 | $1.3M | — | ||
| Q1 23 | $1.3M | — |
| Q4 25 | — | $-957.9K | ||
| Q3 25 | — | $-1.0M | ||
| Q2 25 | — | $-749.4K | ||
| Q2 24 | — | $-809.2K | ||
| Q4 23 | $-23.9M | — | ||
| Q3 23 | $-17.9M | — | ||
| Q2 23 | $-29.1M | — | ||
| Q1 23 | $-24.8M | — |
| Q4 25 | — | -99.0% | ||
| Q3 25 | — | -263.9% | ||
| Q2 25 | — | -574.8% | ||
| Q2 24 | — | — | ||
| Q4 23 | -2450.8% | — | ||
| Q3 23 | -1858.6% | — | ||
| Q2 23 | -2226.1% | — | ||
| Q1 23 | -1624.8% | — |
| Q4 25 | — | -77.2% | ||
| Q3 25 | — | -201.0% | ||
| Q2 25 | — | -438.3% | ||
| Q2 24 | — | — | ||
| Q4 23 | -2634.0% | — | ||
| Q3 23 | -1541.1% | — | ||
| Q2 23 | -2222.0% | — | ||
| Q1 23 | -1932.6% | — |
| Q4 25 | — | $-0.13 | ||
| Q3 25 | — | $-0.14 | ||
| Q2 25 | — | $-0.11 | ||
| Q2 24 | — | $-0.72 | ||
| Q4 23 | $-0.58 | — | ||
| Q3 23 | $-0.45 | — | ||
| Q2 23 | $-0.76 | — | ||
| Q1 23 | $-0.65 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $99.7M | $840.5K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $78.1M | $13.1M |
| Total Assets | $124.5M | $13.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $840.5K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | $4.5M | ||
| Q4 23 | $99.7M | — | ||
| Q3 23 | $117.7M | — | ||
| Q2 23 | $116.9M | — | ||
| Q1 23 | $129.4M | — |
| Q4 25 | — | $13.1M | ||
| Q3 25 | — | $14.1M | ||
| Q2 25 | — | $15.0M | ||
| Q2 24 | — | $4.7M | ||
| Q4 23 | $78.1M | — | ||
| Q3 23 | $96.0M | — | ||
| Q2 23 | $106.0M | — | ||
| Q1 23 | $130.3M | — |
| Q4 25 | — | $13.4M | ||
| Q3 25 | — | $14.3M | ||
| Q2 25 | — | $15.4M | ||
| Q2 24 | — | $5.1M | ||
| Q4 23 | $124.5M | — | ||
| Q3 23 | $141.6M | — | ||
| Q2 23 | $142.1M | — | ||
| Q1 23 | $155.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-20.6M | $-733.1K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-733.1K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | — | $-716.9K | ||
| Q2 24 | — | $-738.5K | ||
| Q4 23 | $-20.6M | — | ||
| Q3 23 | $-16.6M | — | ||
| Q2 23 | $-13.8M | — | ||
| Q1 23 | $-13.3M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
